First Trust Advisors LP Boosts Stock Holdings in DexCom, Inc. $DXCM

First Trust Advisors LP lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 19.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,014,459 shares of the medical device company’s stock after acquiring an additional 163,818 shares during the quarter. First Trust Advisors LP owned approximately 0.26% of DexCom worth $68,263,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Marshall Wace LLP increased its holdings in DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after buying an additional 2,762,504 shares during the last quarter. E. Ohman J or Asset Management AB boosted its stake in DexCom by 400.2% in the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock valued at $5,214,000 after acquiring an additional 62,000 shares during the last quarter. Zevenbergen Capital Investments LLC boosted its stake in DexCom by 10.0% in the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock valued at $46,123,000 after acquiring an additional 62,098 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after acquiring an additional 21,352 shares during the period. Finally, NEOS Investment Management LLC grew its position in shares of DexCom by 58.7% during the 3rd quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after acquiring an additional 65,066 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DXCM shares. Barclays reaffirmed an “underweight” rating and issued a $72.00 price target (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Sanford C. Bernstein reissued an “outperform” rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Robert W. Baird set a $87.00 target price on DexCom in a research note on Friday, February 13th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: BTIG reaffirmed its “buy” rating and set an $85 price target (roughly mid-teens upside from current levels), supporting upside expectations for DXCM. BTIG Reaffirmed Buy
• Positive Sentiment: Zacks published a bullish take, highlighting DexCom as a strong growth stock based on style and growth metrics — a positive signal for momentum investors. Zacks: Here’s Why DexCom is a Strong Growth Stock
• Positive Sentiment: Analysts’ consensus remains constructive: coverage aggregation shows a “Moderate Buy” consensus, which can anchor expectations for further upgrades or positive revisions. Analyst Consensus: Moderate Buy
• Positive Sentiment: The Motley Fool included DexCom in a piece on growth stocks to hold long term, reinforcing the narrative that DXCM is a multi-year growth story for buy-and-hold investors. Fool: 2 Growth Stocks to Hold
• Neutral Sentiment: Benzinga published a roundup of 12 analyst reviews that helps parse differing price targets and ratings — useful for investors but not a single catalytic item. Benzinga: Demystifying DexCom
• Neutral Sentiment: MarketWatch noted DexCom “outperformed competitors despite losses on the day,” indicating relative strength but also highlighting intraday selling pressure; this is mixed for near-term price action. MarketWatch: DexCom Outperforms Competitors
• Neutral Sentiment: Reports show a purported “large increase” in short interest for March, but the published short-interest figures appear contradictory/erroneous (zeros and NaN). The data anomaly limits interpretability — if real, rising shorts would be negative; as reported, treat it as unreliable.

DexCom Trading Down 1.4%

Shares of DexCom stock opened at $67.79 on Wednesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a market cap of $26.09 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 1.34 and a beta of 1.48. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $70.73 and its 200-day moving average price is $68.57.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 earnings per share. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.